| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/01/2013 | CA2858105A1 Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them |
| 08/01/2013 | CA2857969A1 (1r,4r) 7-oxo-2-azabicyclo[2.2.2]oct-5-ene and derivatives thereof |
| 08/01/2013 | CA2857046A1 Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof |
| 08/01/2013 | CA2856892A1 Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines |
| 08/01/2013 | CA2854986A1 Novel galactoside inhibitors of galectins |
| 07/31/2013 | EP2620492A1 Platelet-derived growth factor-bb production promoter, and mesenchymal stem cell production promoter, stem cell stabilizer and dermis regenerator each comprising same |
| 07/31/2013 | EP2620443A1 Novel galactoside inhibitors of galectins |
| 07/31/2013 | EP2620439A1 8-pyrazinyl-S-spiropyrimidinetrione-oxazinoquinoline derivatives as antibacterial agents |
| 07/31/2013 | EP2620438A1 Substituted pyrano and furanoquinolines, their preparation and use as medicaments |
| 07/31/2013 | EP2620437A1 Benzomorphan compounds |
| 07/31/2013 | EP2620436A1 Substituted polycyclic carbamoyl pyridone derivative prodrug |
| 07/31/2013 | EP2620435A1 Phenyl and benzodioxinyl substituted indazole derivatives |
| 07/31/2013 | EP2620434A1 Crystals of substituted cycloalkene derivatives |
| 07/31/2013 | EP2620433A1 Substituted amide compound |
| 07/31/2013 | EP2620432A2 Diarylhydantoin compounds |
| 07/31/2013 | EP2620431A1 Novel crystals of substituted phenylalkanoic acid and production process |
| 07/31/2013 | EP2620429A1 Hydroxylamine compounds and methods of their use |
| 07/31/2013 | EP2620423A1 Improved methods for preparing squalene |
| 07/31/2013 | EP2620161A1 Diblock copolymers and polynucleotide complexes thereof for delivery into cells |
| 07/31/2013 | EP2620154A1 Drug against central nervous system inflammation |
| 07/31/2013 | EP2620153A1 5 alpha-androstane (alkyl)-3 beta,5,6 beta-triol injection and preparation method therefor |
| 07/31/2013 | EP2620152A1 Pharmaceutical composition with antimicrobial activity for parenteral administration and process for preparing same |
| 07/31/2013 | EP2620151A1 Use of adrenergic beta-3-receptor blockers in cancer treatment |
| 07/31/2013 | EP2620150A2 2-Amido Thiazole Based Inhibitors of ATP-Utilizing Enyzmes |
| 07/31/2013 | EP2620149A2 Use of dimiracetam in the treatment of chronic pain |
| 07/31/2013 | EP2620148A1 Antitumoral combination comprising cabazitaxel and cisplatin |
| 07/31/2013 | EP2620147A2 Compounds of lowering cholesterol |
| 07/31/2013 | EP2620146A1 Ibuprofen for treating actinic keratosis |
| 07/31/2013 | EP2620145A2 2,5-dihydroxybenzene compounds for the treatment of of cancer of an organ |
| 07/31/2013 | EP2620144A1 Staining Composition |
| 07/31/2013 | EP2620143A1 Adrenergic beta-3-receptor agonists for use in treatment of aging-related diseases |
| 07/31/2013 | EP2620142A1 Hedgehog signaling pathway involved in energy metabolism |
| 07/31/2013 | EP2620141A1 Thin film drug delivery system for the transmucosal administration of a 1,4-benzoquinone derivative |
| 07/31/2013 | EP2620140A1 Crizotinib containing compositions |
| 07/31/2013 | EP2619331A1 Methods of treating cancer comprising targeting nqo1 |
| 07/31/2013 | EP2619310A2 A nucleic acid having an anti-metabolic syndrome effect |
| 07/31/2013 | EP2619309A1 Sirna against p22phox |
| 07/31/2013 | EP2619238A1 Novel block copolymer and micelle compositions and methods of use thereof |
| 07/31/2013 | EP2619216A1 Substituted nucleotide analogs |
| 07/31/2013 | EP2619215A1 Azido nucleosides and nucleotide analogs |
| 07/31/2013 | EP2619212A1 Buprenorphine analogs |
| 07/31/2013 | EP2619209A1 Atropisomers of pi3k-inhibiting compounds |
| 07/31/2013 | EP2619208A1 Imidazotriazinone compounds |
| 07/31/2013 | EP2619207A1 4,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-6-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) |
| 07/31/2013 | EP2619206A1 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
| 07/31/2013 | EP2619205A1 Monohydrate of an azaadamantane derivative |
| 07/31/2013 | EP2619203A1 Tricyclic compounds, preparation methods, and their uses |
| 07/31/2013 | EP2619202A1 Pyridmidones for treatment of potassium channel related diseases |
| 07/31/2013 | EP2619201A1 Pyrazolopyridines as inhibitors of the kinase lrrk2 |
| 07/31/2013 | EP2619200A2 Compounds that modulate intracellular calcium |
| 07/31/2013 | EP2619198A1 Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| 07/31/2013 | EP2619197A1 Oxadiazole inhibitors of leukotriene production |
| 07/31/2013 | EP2619196A1 Oxadiazole inhibitors of leukotriene production |
| 07/31/2013 | EP2619195A1 Hepatitis c virus inhibitors |
| 07/31/2013 | EP2619194A1 Fatty acid derivatives of catechins and methods of their use |
| 07/31/2013 | EP2619191A2 Novel polymorphs of febuxostat |
| 07/31/2013 | EP2619190A1 Substituted oxadiazole compounds and their use as s1p1 agonists |
| 07/31/2013 | EP2619189A1 Isoxazoline oximes as antiparasitic agents |
| 07/31/2013 | EP2619188A1 Substituted n-phenethyltriazoloneacetamides and use thereof |
| 07/31/2013 | EP2619187A1 Compounds and pharmaceutical compositions for treating disorders associated with the 5-ht1a and 5-ht2a receptors |
| 07/31/2013 | EP2619185A1 Matrix metalloproteinase inhibitors |
| 07/31/2013 | EP2619184A2 Deubiquitinase inhibitors and methods for use of the same |
| 07/31/2013 | EP2619182A1 Pharmaceutical composition |
| 07/31/2013 | EP2619180A1 5-ht2b receptor antagonists |
| 07/31/2013 | EP2619179A1 Matrix metalloproteinase inhibitors |
| 07/31/2013 | EP2619177A1 Matrix metalloproteinase inhibitors |
| 07/31/2013 | EP2618832A2 Composition comprising sod, lutein and zeaxanthin |
| 07/31/2013 | EP2618828A1 Aprepitant l-proline composition and cocrystal |
| 07/31/2013 | EP2618827A2 Antidiabetic solid pharmaceutical compositions |
| 07/31/2013 | EP2618826A1 Phenylpiperidine compounds for the treatment of neurological and psychiatric disorders |
| 07/31/2013 | EP2618825A1 Use of nigericin to treat and prevent vaccinia virus infections |
| 07/31/2013 | EP2618824A1 Methods and compositions for treatment of diabetes and dyslipidemia |
| 07/31/2013 | EP2618823A1 Xenon-based anesthetic gas composition usable during an endarterectomy involving the clamping of the carotid artery |
| 07/31/2013 | EP2618821A2 Nanostructured gels capable of controlled release of encapsulated agents |
| 07/31/2013 | EP2618820A2 Controlled release formulations of opioids |
| 07/31/2013 | EP2618819A1 Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease |
| 07/31/2013 | EP2618818A1 Corticosteroid particles and method of production |
| 07/31/2013 | EP2618816A2 Aerosol composition for administering drugs |
| 07/31/2013 | EP2618815A2 Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same |
| 07/31/2013 | EP2618814A1 Caspofungin composition |
| 07/31/2013 | EP2618685A2 Trivalent chromium and boron fortifying composition, a hydration supplement, and process for preparing the same |
| 07/31/2013 | EP2618666A1 Novel dihydropyrimidin-2(1h)-one compounds as neurokinin-3 receptor antagonists |
| 07/31/2013 | EP2618665A1 Hcv ns3 protease inhibitors |
| 07/31/2013 | EP2411043B1 Treatment of cancer with immunostimulatory hiv tat derivative polypeptides |
| 07/31/2013 | EP1476185B1 Antibodies to cd40 |
| 07/31/2013 | CN203089942U Tiamulin long-acting particle pill |
| 07/31/2013 | CN1927189B Percutaneous absorption-type pharmaceutical preparations |
| 07/31/2013 | CN103228678A Method for decontaminating starch hydrolysates for the preparation of glucose polymers for peritoneal dialysis |
| 07/31/2013 | CN103228668A Antidiabetic enolic glucoside of phenylpyruvic acid |
| 07/31/2013 | CN103228660A Kat II inhibitors |
| 07/31/2013 | CN103228659A Antifungal 5,6-dihydro-4H-pyrrolo[1,2-A][1,4]-benzodiazepines and 6H-pyrrolo[1,2-A][1,4]benzodiazepines substituted with phenyl derivatives |
| 07/31/2013 | CN103228657A 3-hetaryl-substituted pyrrole[2,3-b]pyridine derivatives as pdk1 inhibitors |
| 07/31/2013 | CN103228656A 3-substituted-6-(pyridinylmethoxy)- pyrrolopyridine compounds |
| 07/31/2013 | CN103228655A Carbazole and carboline derivatives, and preparation and therapeutic applications thereof |
| 07/31/2013 | CN103228654A Imidazo [1,2-b] pyridazine and imidazo [4,5-b] pyridine derivatives as JAK inhibitors |
| 07/31/2013 | CN103228653A Substituted polycyclic carbamoyl pyridone derivative prodrug |
| 07/31/2013 | CN103228652A Monobactams |
| 07/31/2013 | CN103228651A Compounds useful as inhibitors of atr kinase |
| 07/31/2013 | CN103228648A Crystalline forms of (s)-2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl) propanoic acid |
| 07/31/2013 | CN103228644A 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2 |